Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of peritoneal surface malignancies – An evidence-based review

Thomassen, 2013, Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin, Dis Colon Rectum, 56, 1373, 10.1097/DCR.0b013e3182a62d9d Neuwirth, 2016, Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective, J Gastrointest Oncol, 7, 18 Bartlett, 2008, HIPEC: the complexities of clinical trials, Ann Surg Oncol, 15, 1277, 10.1245/s10434-007-9768-y Meigs, 1934 Sugarbaker, 1995, Peritonectomy procedures, Ann Surg, 221, 29, 10.1097/00000658-199501000-00004 Klaver, 2012, Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy, Eur J Surg Oncol, 38, 617, 10.1016/j.ejso.2012.03.008 Hildebrandt, 2002, The cellular and molecular basis of hyperthermia, Crit Rev Oncol Hematol, 43, 33, 10.1016/S1040-8428(01)00179-2 Ceelen, 2009, Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence, Nat Rev Clin Oncol, 2010, 108 de Bree, 2007, Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis, Recent Results Cancer Res, 169, 39 de Bree, 2007, Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside, Recent Results Cancer Res, 169, 53 de Bree, 2015, Optimal drugs for hipec in different tumors, J BUON, 20, S40 Piso, 2009, Patient selection for a curative approach to carcinomatosis, Cancer J, 15, 236, 10.1097/PPO.0b013e3181a58f30 Yan, 2008, Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement, J Surg Oncol, 98, 224, 10.1002/jso.21069 González-Moreno, 2009, Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy, J Surg Oncol, 100, 287, 10.1002/jso.21325 Ashvin, 2016, Preoperative management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, Indian J Surg Oncol, 8, 573, 10.1007/s13193-016-0517-1 Sugarbaker, 2005 Glehen, 2003, Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures, Ann Surg Oncol, 10, 863, 10.1245/ASO.2003.01.018 Goldenshluger, 2018, Core body temperature but not intraabdominal pressure predicts postoperative complications following closed-system Hyperthermic Intraperitoneal Chemotherapy (HIPEC) administration, Ann Surg Oncol, 25, 660, 10.1245/s10434-017-6279-3 Leiting, 2020, Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative, World J Gastrointest Oncol, 12, 756, 10.4251/wjgo.v12.i7.756 Ronnett, 1995, Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei, Am J Surg Pathol, 19, 1390, 10.1097/00000478-199512000-00006 Ronnett, 2001, Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis, Cancer, 92, 85, 10.1002/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R Mohamed, 2011, A new standard of care for the management of peritoneal surface malignancy, Curr Oncol, 18, e84, 10.3747/co.v18i2.663 Moran, 2008, Consensus statement on the locoregional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei), J Surg Oncol, 98, 277, 10.1002/jso.21054 Yan, 2007, A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei, Ann Surg Oncol, 14, 484, 10.1245/s10434-006-9182-x Sugarbaker, 1999, Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy, Ann Surg Oncol, 6, 727, 10.1007/s10434-999-0727-7 Chua, 2012, Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, J Clin Oncol, 30, 2449, 10.1200/JCO.2011.39.7166 Miner, 2005, Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy, Ann Surg, 241, 300, 10.1097/01.sla.0000152015.76731.1f Glehen, 2010, oward curative treatment of peritoneal carcinomatosis from non ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients, Cancer, 116, 5608, 10.1002/cncr.25356 Kuijpers, 2013, Cytoreduction and hipec in the Netherlands: nationwide long-term outcome following the Dutch protocol, Ann Surg Oncol, 20, 4224, 10.1245/s10434-013-3145-9 Taflampas, 2014, Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients, Eur J Surg Oncol, 40, 515, 10.1016/j.ejso.2013.12.021 Ansari, 2016, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours, Eur J Surg Oncol, 42, 1035, 10.1016/j.ejso.2016.03.017 Sinukumar, 2019, Analysis of clinical outcomes of pseudomyxoma peritonei from appendicular origin following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a retrospective study from INDEPSO, Indian J Surg Oncol, 10, 65, 10.1007/s13193-018-00870-w Auer, 2020, Response to letter commenting on 'indications for hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery: a systematic review, Eur J Cancer, 139, 188, 10.1016/j.ejca.2020.07.013 Lord, 2015, Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours, Eur J Surg Oncol, 41, 396, 10.1016/j.ejso.2014.08.476 Delhorme, 2017, Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei, Eur J Surg Oncol, 43, 159, 10.1016/j.ejso.2016.08.021 Mohamed, 2003, Third looksurgery and beyond for appendiceal malignancy with peritoneal dissemination, J Surg Oncol, 83, 5, 10.1002/jso.10234 Boffetta, 2007, Epidemiology of peritoneal mesothelioma: a review, Ann Oncol, 18, 985, 10.1093/annonc/mdl345 Sugarbaker, 2003, A review of peritoneal mesothelioma at the Washington Cancer Institute, Surg Oncol Clin N Am, 12, 605, 10.1016/S1055-3207(03)00045-0 Baratti, 2011, Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research, J Surg Oncol, 103, 822, 10.1002/jso.21787 Manzini Vde, 2010, Malignant peritoneal mesothelioma: a multicentre study on 81 cases, Ann Oncol, 21, 348, 10.1093/annonc/mdp307 Yan, 2009, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience, J Clin Oncol, 27, 6237, 10.1200/JCO.2009.23.9640 Helm, 2015, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis, Ann Surg Oncol, 22, 1686, 10.1245/s10434-014-3978-x Malgras, 2018, Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study, Ann Surg Oncol, 25, 3271, 10.1245/s10434-018-6631-2 Deraco, 2013, The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, Ann Surg Oncol, 20, 1093, 10.1245/s10434-012-2845-x Bijelic, 2012, Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma, Gastroenterol Res Pract, 2012, 10.1155/2012/890450 Baratti, 2013, Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC), Eur J Cancer, 49, 3140, 10.1016/j.ejca.2013.05.027 Wong, 2014, Repeat cytoreductive surgery and hipec may offer survival benefit for intraperitoneal mesothelioma: a single institution experience, Ann Surg Oncol, 21, 1480, 10.1245/s10434-013-3341-7 Kim, 2017, Malignant peritoneal mesothelioma: a review, Ann Transl Med, 5, 236, 10.21037/atm.2017.03.96 Magge, 2014, Malignant peritoneal mesothelioma prognostic factors and oncologic outcome analysis, Ann Surg Oncol, 21, 1159, 10.1245/s10434-013-3358-y Jr, 2013, Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma, Surgery, 153, 779, 10.1016/j.surg.2013.01.001 Jayne, 2002, Peritoneal carcinomatosis from colorectal cancer, Br J Surg, 89, 1545, 10.1046/j.1365-2168.2002.02274.x Segelman, 2012, Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer, Br J Surg, 99, 699, 10.1002/bjs.8679 van Gestel, 2014, Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer, Eur J Surg Oncol, 40, 963, 10.1016/j.ejso.2013.10.001 Verwaal, 2003, Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, J Clin Oncol, 21, 3737, 10.1200/JCO.2003.04.187 Verwaal, 2008, 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer, Ann Surg Oncol, 15, 2426, 10.1245/s10434-008-9966-2 Chua, 2013, Summary of current therapeutic options for peritoneal metastases from colorectal cancer, J Surg Oncol, 107, 566, 10.1002/jso.23189 Huang, 2017, Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence, Oncotarget, 8, 55657, 10.18632/oncotarget.17497 Chua, 2009, Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection, Eur J Surg Oncol, 35, 1299, 10.1016/j.ejso.2009.07.005 Leung, 2017, Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis, Eur J Surg Oncol, 43, 144, 10.1016/j.ejso.2016.09.015 Hompes, 2014, The use of oxaliplatin or mitomycin C in hipec treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study, J Surg Oncol, 109, 527, 10.1002/jso.23546 Honoré, 2012, Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review, Ann Surg Oncol, 20, 183, 10.1245/s10434-012-2473-5 Elias, 2011, Results of systematic second-look surgery plus hipec in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis, Ann Surg, 254, 289, 10.1097/SLA.0b013e31822638f6 Yan, 2006, Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma, J Clin Oncol, 24, 4011, 10.1200/JCO.2006.07.1142 Quénet, 2018, A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7, J Clin Oncol, 36, 10.1200/JCO.2018.36.18_suppl.LBA3503 Gill, 2011, Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and hipec: a systematic review of survival, mortality, and morbidity, J Surg Oncol, 104, 692, 10.1002/jso.22017 Coccolini, 2014, Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials, Eur J Surg Oncol, 40, 12, 10.1016/j.ejso.2013.10.019 Zhentian, 2016, Meta-analysis of the efficacy and safety of intraperitoneal hyperthermic chemotherapy in the treatment of advanced gastric cancer during operation combined with surgery, Chin J Gastrointest Surg, 19, 1406 Gong, 2019, Benefits of surgery after NIPS for GC patients with peritoneal metastasis: a meta-analysis, J Surg Res, 245, 234, 10.1016/j.jss.2019.07.044 Desiderio, 2017, The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer, Eur J Cancer, 79, 1, 10.1016/j.ejca.2017.03.030 Fujimura, 2000, Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer, Oncol Rep, 7, 809 Bhatt, 2016, The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review, Indian J Surg Oncol, 7, 188, 10.1007/s13193-016-0501-9 Bhatt, 2019, Impact of Radicality Versus Timing of Surgery in Patients with Advanced Ovarian Cancer (Stage III C) Undergoing CRS and HIPEC—a Retrospective Study by INDEPSO, Indian J Surg Oncol, 10, 57, 10.1007/s13193-019-00875-z Mulier, 2012, Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different timepoints of treatment of ovarian cancer: review of evidence, Curr Pharm Des, 18, 3793, 10.2174/138161212802002616 Fagotti, 2011, HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome, Gynecol Oncol, 122, 221, 10.1016/j.ygyno.2011.04.008 Bakrin, 2013, Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of566 patients, Eur J Surg Oncol, 39, 1435, 10.1016/j.ejso.2013.09.030 Spiliotis, 2015, Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study, Ann Surg Oncol, 22, 1570, 10.1245/s10434-014-4157-9 Van Driel, 2018, Hyperthermic intraperitoneal chemotherapy in ovarian cancer, N Engl J Med, 378, 230, 10.1056/NEJMoa1708618 Vergote, 2019, Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer, Cancer, 125, 4594, 10.1002/cncr.32496 Lim, 2017, Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer, J Clin Oncol, 35, 5520, 10.1200/JCO.2017.35.15_suppl.5520 Walker, 2019, Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study, J Clin Oncol, 37, 1380, 10.1200/JCO.18.01568 Lei, 2020, Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for Stage III epithelial ovarian cancer, JAMA Netw Open, 3, 10.1001/jamanetworkopen.2020.13940 Alter, 2020, Are we ready for hyperthermic intraperitoneal chemotherapy in the upfront treatment of ovarian cancer?, JAMA Netw Open, 3, 10.1001/jamanetworkopen.2020.14184 Rossi, 2008, The consensus statement on the locoregional treatment of abdominal sarcomatosis, J Surg Oncol, 98, 291, 10.1002/jso.21067 Potter, 1985, Patterns of recurrence in patients with high grade soft tissue sarcomas, J ClinOncol, 3, 353, 10.1200/JCO.1985.3.3.353 Rossi, 2004, Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis, Cancer, 100, 1943, 10.1002/cncr.20192 Baratti, 2010, Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?, Ann Surg Oncol, 17, 3220, 10.1245/s10434-010-1178-x Sardi, 2018, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma, Clin Case Rep, 6, 1142, 10.1002/ccr3.1491 Sommariva, 2013, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long term outcome from a single institution experience, Anticancer Res, 33, 3989 Abu-Zaid, 2016, Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for management of peritoneal sarcomatosis: a preliminary single-center experience from Saudi Arabia, Gastroenterol Res Pract, 1, 10.1155/2016/6567473 Inoue, 2015, Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination, Gynecol Oncol Rep, 13, 60, 10.1016/j.gore.2015.06.010 Salti, 2012, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis, Ann Surg Oncol, 19, 1410, 10.1245/s10434-012-2240-7 Goéré, 2017, Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI), Int J Hyperthermia, 33, 520, 10.1080/02656736.2017.1301576